Your browser is no longer supported. Please, upgrade your browser.
SAVA Cassava Sciences, Inc. daily Stock Chart
Cassava Sciences, Inc.
Index- P/E- EPS (ttm)-0.23 Insider Own10.47% Shs Outstand24.48M Perf Week8.48%
Market Cap77.05M Forward P/E- EPS next Y-0.34 Insider Trans0.00% Shs Float22.19M Perf Month31.91%
Income-4.40M PEG- EPS next Q-0.06 Inst Own25.30% Short Float15.27% Perf Quarter-38.36%
Sales- P/S- EPS this Y56.70% Inst Trans0.07% Short Ratio0.79 Perf Half Y-54.92%
Book/sh1.01 P/B3.36 EPS next Y-25.90% ROA-20.40% Target Price- Perf Year140.43%
Cash/sh1.13 P/C3.01 EPS next 5Y- ROE-21.50% 52W Range1.03 - 10.95 Perf YTD-34.81%
Dividend- P/FCF- EPS past 5Y32.60% ROI- 52W High-69.04% Beta2.98
Dividend %- Quick Ratio22.60 Sales past 5Y- Gross Margin- 52W Low229.13% ATR0.36
Employees9 Current Ratio22.60 Sales Q/Q- Oper. Margin- RSI (14)60.25 Volatility15.67% 10.56%
OptionableYes Debt/Eq0.00 EPS Q/Q40.70% Profit Margin- Rel Volume0.62 Prev Close3.65
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume4.31M Price3.39
Recom3.00 SMA2011.79% SMA50-8.16% SMA200-19.08% Volume2,655,445 Change-7.12%
May-18-20Downgrade H.C. Wainwright Buy → Neutral
May-15-20Downgrade Maxim Group Buy → Hold
Jan-10-20Reiterated Maxim Group Buy $3 → $12
Jul-14-20 08:44AM  
Jul-09-20 04:01PM  
Jun-16-20 08:15AM  
Jun-10-20 04:33PM  
Jun-03-20 08:15AM  
May-19-20 07:57PM  
May-15-20 02:05PM  
May-06-20 08:48AM  
May-03-20 07:30PM  
Apr-24-20 10:03AM  
Apr-23-20 08:15AM  
Apr-13-20 01:25PM  
Mar-26-20 08:15AM  
Mar-25-20 08:15AM  
Mar-19-20 08:15AM  
Mar-02-20 11:04AM  
Feb-11-20 08:15AM  
Jan-28-20 08:15AM  
Jan-10-20 09:33AM  
Jan-09-20 06:19AM  
Jan-08-20 11:23AM  
Jan-07-20 09:03AM  
Jan-06-20 05:05AM  
Jan-03-20 10:36AM  
Jan-02-20 10:19AM  
Dec-27-19 02:19PM  
Dec-10-19 07:42AM  
Dec-06-19 03:08PM  
Dec-05-19 09:00PM  
Dec-04-19 09:26AM  
Dec-01-19 09:30AM  
Nov-05-19 12:06PM  
Oct-29-19 08:15AM  
Oct-24-19 08:30AM  
Sep-20-19 10:02AM  
Sep-16-19 08:30AM  
Sep-09-19 02:42PM  
Sep-06-19 11:50AM  
Sep-03-19 08:30AM  
Aug-12-19 08:30AM  
Jul-08-19 02:51PM  
Jun-18-19 08:30AM  
May-28-19 08:29AM  
May-23-19 04:35PM  
May-16-19 10:36AM  
Apr-29-19 08:30AM  
Apr-15-19 08:30AM  
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARBIER REMIPresident and CEODec 31Buy5.53100,000553,0001,068,855Dec 31 04:10 PM
BARBIER REMIPresident and CEODec 26Buy4.1510,00041,500968,855Dec 26 04:03 PM
ROBERTSON SANFORDDirectorDec 20Buy2.20423,788932,334662,623Dec 20 04:11 PM
Schoen EricChief Financial OfficerDec 19Buy1.885,3009,96415,300Dec 19 06:06 PM
ROBERTSON SANFORDDirectorDec 19Buy1.8676,212141,754238,835Dec 19 06:04 PM
BARBIER REMIPresident and CEODec 18Buy1.652,5994,2882,599Dec 20 04:13 PM